W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity
Gabriel E. Büchel,Iryna N. Stepanenko,Michaela Hejl,Michael A. Jakupec,Michael A. Jakupec,Bernhard K. Keppler,Bernhard K. Keppler,Petra Heffeter,Walter Berger,Vladimir B. Arion +9 more
TL;DR: A one-pot synthesis of osmium(IV) complexes with two different tautomers of indazole, 1H-indazole and 2H- Indazoles, namely (H2ind)[OsIVCl5(2H-IND)] (1) and (H1H-Indazole) (2) is reported.
Journal ArticleDOI
P-glycoprotein regulates chemosensitivity in early developmental stages of the mouse.
TL;DR: Evidence is provided that MDR‐P‐gp has an efficient protective function in early reproduction and that multidrug (chemo)resistance is already present in mouse oocytes and early cleavage embryos.
Journal ArticleDOI
Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
Diana Groza,Sebastian Gehrig,Pavol Kudela,Martin Holcmann,Christine Pirker,Carina Dinhof,Hemma Schueffl,Marek Sramko,Julia Hoebart,Fatih Alioglu,Michael Grusch,Manfred Ogris,Werner Lubitz,Bernhard K. Keppler,Bernhard K. Keppler,Irena Pashkunova-Martic,Christian R. Kowol,Christian R. Kowol,Maria Sibilia,Walter Berger,Petra Heffeter +20 more
TL;DR: It is shown that the combination of BGs with oxaliplatin treatment had strong synergistic anticancer activity against the CT26 allograft, resulting in prolonged survival and even a complete remission in this murine model of CRC carcinomatosis.
Journal ArticleDOI
Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?
Jakob Paur,Lisa Nika,Christiane Maier,Alexander Moscu-Gregor,Julia Kostka,Daniela Huber,Thomas Mohr,Petra Heffeter,Waltraud C. Schrottmaier,Sonja Kappel,Daniela Kandioler,Klaus Holzmann,Brigitte Marian,Walter Berger,Michael Grusch,Bettina Grasl-Kraupp +15 more
TL;DR: In this article, the authors provided mechanistic insight that FGFR3 splice variants IIIb and IIIc impact considerably on the malignant phenotype of hepatocellular carcinoma (HCC) cells.
Journal ArticleDOI
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Melanie Spitzwieser,Christine Pirker,Bettina Koblmüller,Georg Pfeiler,Stefan Hacker,Walter Berger,Petra Heffeter,Margit Cichna-Markl +7 more
TL;DR: The data indicates that hypomethylation of the ABCC1 promoter is not cancer type-specific but occurs in cancer cell lines of different origins, and promoter methylation was found to be an important mechanism in gene regulation of ABCB1 in parental cancer cell Lines and their drug-resistant sublines.